Form D · Biotechnology
Jasper Therapeutics, Inc.
Redwood City, CA · CIK 0001788028
Offering snapshot reported Aug 5, 2026 · SEC filing
- Reported sold
- $132M Offering amount: $132M
- Investors reported
- 40 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 21, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 5, 2026 | Initial | $131,999,611 | No comparison | 40 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-593140
Source: Form D, filed Aug 5, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Herb Cross | Executive |
| Patrick Crutcher | Director |
| Gregory F. Keenan | Executive |
| Svetlana Lucas | Director |
| Jeet Mahal | Director, Executive |
| Matthew E. Ros | Director |
| Judith Shizuru | Director |
| Wenru Song | Executive |
| Kurt Von Emster | Director |
| Thomas Wiggans | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2200 Bridge Pkwy Suite #102
Redwood City, CA, 94065
Phone: 650-549-1400
Redwood City, CA, 94065
Phone: 650-549-1400